(Q48064807)

8 February 2018

http://europepmc.org/abstract/MED/25248002

title

eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis (English)

1 reference

8 February 2018

http://europepmc.org/abstract/MED/25248002

author

Johan Burisch

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Natalia Pedersen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Peter Thielsen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Lars Martinsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Mette Bennedsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Anne Haaber

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Ebbe Langholz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Zsuzsanna Végh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Dana Duricova

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Tine Jess

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Sally Bell

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Pia Munkholm

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

1 December 2014

1 reference

8 February 2018

http://europepmc.org/abstract/MED/25248002

published in

Inflammatory Bowel Diseases

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

2276-2285

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort.

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Changes in extent of ulcerative colitis: a study on the course and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Systematic review: adherence issues in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Predictors of medication adherence in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Mesalamine with MMX technology for the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

European evidence-based Consensus on the management of ulcerative colitis: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

A simple clinical colitis activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Symptom perception and adherence to asthma controller medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

An evidence-based systematic review on medical therapies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000199

10.1097/MIB.0000000000000199

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25248002%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference